Jonathan Yen-Wen Yu Sells 300 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 300 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $82.53, for a total transaction of $24,759.00. Following the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $4,483,359.72. The trade was a 0.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, August 25th, Jonathan Yen-Wen Yu sold 8,796 shares of Disc Medicine stock. The stock was sold at an average price of $83.12, for a total value of $731,123.52.
• On Wednesday, August 12th, Jonathan Yen-Wen Yu sold 804 shares of Disc Medicine stock. The stock was sold at an average price of $82.64, for a total value of $66,442.56.
• On Tuesday, July 7th, Jonathan Yen-Wen Yu sold 100 shares of Disc Medicine stock. The shares were sold at an average price of $82.50, for a total transaction of $8,250.00.
• On Friday, June 26th, Jonathan Yen-Wen Yu sold 300 shares of Disc Medicine stock. The shares were sold at an average price of $72.50, for a total transaction of $21,750.00.
• On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The shares were sold at an average price of $72.66, for a total transaction of $704,802.00.
• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The stock was sold at an average price of $69.19, for a total transaction of $1,287,764.28.

Disc Medicine Price Performance

Shares of IRON stock opened at $82.55 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The company has a market capitalization of $316.58 million, a PE ratio of -12.55 and a beta of 1.00. The firm’s 50-day moving average is $76.79 and its two-hundred day moving average is $69.97. Disc Medicine, Inc. has a 12 month low of $40.00 and a 12 month high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. Analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IRON has been the subject of several recent analyst reports. Wedbush reissued an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a research note on Wednesday, June 10th. Morgan Stanley reiterated an “overweight” rating and set a $90.00 price target on shares of Disc Medicine in a report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wall Street Zen raised Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. Finally, HC Wainwright boosted their price objective on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $106.50.

Institutional Trading of Disc Medicine

Several institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming acquired a new position in Disc Medicine during the second quarter worth $25,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Disc Medicine during the fourth quarter worth $33,000. Allworth Financial LP acquired a new stake in shares of Disc Medicine in the second quarter valued at $46,000. Nykredit A S acquired a new stake in shares of Disc Medicine in the second quarter valued at $103,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Disc Medicine in the 4th quarter valued at $141,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.